RETINAL SOLUTIONS LLC has a total of 11 patent applications. Its first patent ever was published in 2010. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SANOFI BIOTECHNOLOGY, AFFIRIS AG and HAMLET PHARMA AB.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Drenser Kimberly | 11 |
#2 | Trese Michael T | 8 |
#3 | Capone Antonio | 4 |
#4 | Capone Jr Antonio | 2 |
#5 | Mitton Kenneth | 2 |
#6 | Dailey Wendelin | 2 |
#7 | Roumayah Kevin | 1 |
Publication | Filing date | Title |
---|---|---|
US2019169247A1 | Retinal capillary regeneration with synthetic norrin protein | |
US2020268838A1 | Norrin induced expression of genes and use thereof to treat disease | |
US2015352184A1 | Method and compositions for genetic and retinal disease | |
US2016354435A1 | Norrin regulation of junction proteins and the use thereof to treat epithelial or endothelial membrane leakage induced edema | |
US2016355559A1 | Norrin regulation of cellular production of junction proteins and use to treat retinal vasculature edema | |
WO2011050096A2 | Methods and compositions for diagnosis and treatment of genetic and retinal disease |